SEC Form 4 · accession 0001193125-26-290475
Inhibikase Therapeutics, Inc. · IKT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arvind Kush
Director
Period of report
Jun 26, 2026
Accepted (ET)
Jun 30, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001750149
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.91 | Jun 26, 2026 | A | 155,000 | A | — | Jun 26, 2036 | Common Stock | 155,000 | 155,000 | D |
Explanation of responses
- F1The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.